Factors for grade II-IV aGVHD (N = 191)
| . | n (%) . | P, multivariate . | HR (95% CI) . |
|---|---|---|---|
| Sex | .460 | 0.830 (0.504-1.367) | |
| Male | 111 (58) | ||
| Female | 80 (42) | ||
| Age, y | .360 | 0.763 (0.428-1.359) | |
| ≥55 | 73 (38) | ||
| <55 | 118 (62) | ||
| Disease risk* | .120 | 1.463 (0.906-2.361) | |
| High | 96 (50) | ||
| Low | 95 (50) | ||
| No. of transplantations | .870 | 0.950 (0.503-1.793) | |
| >1 | 24 (13) | ||
| 1 | 167 (87) | ||
| Conditioning | .250 | 1.403 (0.790-2.493) | |
| MAC | 108 (57) | ||
| RIC | 83 (43) | ||
| Donor-recipient sex | .120 | 0.580 (0.291-1.154) | |
| Female to male | 26 (14) | ||
| Others | 165 (86) | ||
| HLA disparity | .380 | 1.230 (0.773-1.957) | |
| 0 | 85 (45) | ||
| ≥1 | 106 (55) | ||
| Type of transplantation | .100 | 0.491 (0.208-1.157) | |
| rPBSCT | 24 (13) | ||
| Others | 167 (87) | ||
| Use of antibiotics with relatively high antianaerobic activity (conditioning to day 28)† | .470 | 1.275 (0.660-2.462) | |
| Yes | 155 (81) | ||
| No | 36 (19) | ||
| Prebiotics | .009 | 0.495 (0.293-0.836) | |
| Yes | 49 (26) | ||
| No | 142 (74) |
| . | n (%) . | P, multivariate . | HR (95% CI) . |
|---|---|---|---|
| Sex | .460 | 0.830 (0.504-1.367) | |
| Male | 111 (58) | ||
| Female | 80 (42) | ||
| Age, y | .360 | 0.763 (0.428-1.359) | |
| ≥55 | 73 (38) | ||
| <55 | 118 (62) | ||
| Disease risk* | .120 | 1.463 (0.906-2.361) | |
| High | 96 (50) | ||
| Low | 95 (50) | ||
| No. of transplantations | .870 | 0.950 (0.503-1.793) | |
| >1 | 24 (13) | ||
| 1 | 167 (87) | ||
| Conditioning | .250 | 1.403 (0.790-2.493) | |
| MAC | 108 (57) | ||
| RIC | 83 (43) | ||
| Donor-recipient sex | .120 | 0.580 (0.291-1.154) | |
| Female to male | 26 (14) | ||
| Others | 165 (86) | ||
| HLA disparity | .380 | 1.230 (0.773-1.957) | |
| 0 | 85 (45) | ||
| ≥1 | 106 (55) | ||
| Type of transplantation | .100 | 0.491 (0.208-1.157) | |
| rPBSCT | 24 (13) | ||
| Others | 167 (87) | ||
| Use of antibiotics with relatively high antianaerobic activity (conditioning to day 28)† | .470 | 1.275 (0.660-2.462) | |
| Yes | 155 (81) | ||
| No | 36 (19) | ||
| Prebiotics | .009 | 0.495 (0.293-0.836) | |
| Yes | 49 (26) | ||
| No | 142 (74) |
CI, confidence interval; HR, hazard ratio.
Low-risk disease included acute leukemia in the first CR, CML in first chronic phase, MDS in refractory anemia, malignant lymphoma in CR, and nonmalignant hematologic diseases. All other diagnoses and second allo-HSCT were included in high-risk disease.
Antibiotics with relatively high antianaerobic activity: meropenem, imipenem-cilastatin, and piperacillin-tazobactam. The other antibiotics were third- and fourth-generation cephems, polypeptides, quinolones, sulfamethoxazole-trimethoprim, aminoglycosides, and aztreonam.